natgillin/translations-raw huggingface dataset:
mg/ml of an anti-PRLR antibody, wherein said anti-PRLR antibody formulation has a pH ranging from pH 5.0 to pH 6.5, wherein said anti-PRLR antibody formulation contains no inorganic salt and wherein said anti-PRLR antibody is a human IgG2 monoclonal antibody which comprises a heavy chain and a light chain, wherein the amino acid sequence of said heavy chain is according to SEQ ID NO: 7, and the amino acid sequence of said light chain is according to SEQ ID NO: 1. 
mg/ml anti-PRLR protutijela, naznačena time što navedena formulacija anti-PRLR protutijela ima pH u rasponu od pH 5.0 do pH 6.5, pri čemu navedena formulacija anti-PRLR protutijela ne sadrži anorgansku sol i pri čemu navedeno anti-PRLR protutijelo je ljudsko IgG2 monoklonsko protutijelo koje sadrži teški lanac i lagani lanac, pri čemu aminokiselinska sekvenca navedenog teškog lanca je u skladu sa SEQ ID NO: 7, i aminokiselinska sekvenca navedenog laganog lanca je u skladu sa SEQ ID NO: 1.
the anaesthetic is selected from the group consisting of lignocaine (lidocaine), amethocaine (tetracaine), xylocaine, bupivacaine, prilocaine, ropivacaine, benzocaine, mepivocaine, cocaine or a mixture thereof. 
je anestetik odabran iz grupe koja se sastoji od lignokaina (lidokaina), ametokaina (tetrakaina), ksilokaina, bupivakaina, prilokaina, ropivakaina, benzokaina, mepivakaina, kokaina ili njihove smjese.
The software may also be able to receive information transmitted from the programmable electrical control device via the USB port 22 a, including a present state of switching times for the programmable electrical control device 10 . 
Programabilni električni upravljački uređaj (10) sukladno bilo kojem zahtjeva 1 do 8, naznačen time da je cijeli programabilni električni upravljački uređaj (12) smješten unutar tijela.
Process according to any of claims 1 to 15, characterised in that the aliphatic carboxylic acid is a 1:1 stearic acid:palmitic acid mixture, and the aliphatic carboxylic acid salt(s) is a magnesium or calcium stearate. 
Postupak prema bilo kojem od zahtjeva 1 do 15, naznačen time da je alifatska karboksilna kiselina mješavina u omjeru 1:1 stearinske kiseline i palmitinske kiseline, a soli alifatske karboksilne kiseline su magnozij ili kalcij stearat.
To stabilise the IL-2 during lyophilisation, a ¼ volume of a 20% mannitol solution was added, to give a final mannitol concentration of 5% (i.e. 50mg/ml). 
Da se stabilizira IL-2 za vrijeme liofilizacije, dodalo se "4 volumena otopine 20% manitola, da dade konačnu koncentraciju manitola od 5% (t.j. 50 mg/ml).
The obtained solution (80 ml) of 7-ethyl-1,2,6,7-tetrahydrocamptothecin is immediately added under vigorous stirring into a 250 ml one-necked flask containing 22 ml (1.218 mol) of water and 0.77 g (2.343 mmol) of iodobenzene diacetate. 
Dobivenu otopina (80 ml) 7-etil-1,2,6,7-tetrahidrokamptotecina se uz snažno mijerešanje odmah doda u jednogrlutikvicu od 250 ml s 22 ml (1,218 mol) vode i 0,77 g (2.343 mmol) jodobenzen-diacetata.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof, are provided for use in the treatment and/or prophylaxis of a condition selected from macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1. 
HR P20151039 T1 PATENTNI ZAHTJEVI Eikozapentaenoična kiselina (EPA) i dokozaheksaenoična kiselina (DHA), ili njihova sol ili ester, za upotrebu u liječenju stanja odabranog iz skupine koja se sastoji od makularnog edema, stanja koja uzrokuju oštećenja fotoreceptora retine i/ili retinalnog pigmenta epitelialnih stanica, 1 suhe oči kod sisavca, naznačen time da je kombinirana doza eikozapentaenoične kiseline i dokozaheksaenoične kiseline od 5 mmol do 25 mmol dnevno, i pri čemu je molarni omjer eikozapentaenoične kiseline prema dokozaheksaenoičnoj kiselini u rasponu od 1: 1do 5:1.
Preferably said composition is used to improve growth, survival and/or malpigmentation of an animal, preferably of an aquatic animal. 
Sastav prema zahtjevu 21 za poboljšanje rasta, preživljavanja i/ili poremećaja pigmentacije kod životinja, poželjno kod akvatičnih životinja.
is a C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene; and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, nitro, Me3Sn and halo; where R and R′ are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; 
R'je Cs.o aril-skupina, opcijski supstituirana s jednim ili više supstituenata odabranih iz skupine koju čine: halo, nitro, cijano, Ci; alkoksi, Cs.29 ariloksi, C2.)9 hetercikliloksi, Ci.7 alkil, C3.; heterociklil 1 bis-oksi-C,.3 alkilen, pri čemu C1; alkoksi-skupina može biti supstituirana s amino-skupinom, i ako je C3.; heterociklil-skupina takva da je to heterociklil-skupina koja sadrži Cg nitrogen, tada može biti supstituirana s C,_., alkil-skupinom;
from 0.05 to 5% by weight, more preferably from 0.1 to 2% by weight, of at least one fluidizing agent; 
(d) od 0,05 do 5 % po masi barem jednog sredstva za superfluidiziranje; naznačen time što sastav sadrži:
The recombinant FVIII protein of any one of claims 1 to 7, wherein the at least one heterologous moiety comprises a peptide or polypeptide which enables visualization or localization of the recombinant FVIII protein in vitro, in vivo, ex vivo, or any combination thereof; wherein the peptide or polypeptide which enables visualization or localization is selected from: 
HR P20190454 T1 Rekombinantni FVIII protein prema bilo kojem od zahtjeva 1 do 7, naznačen time što barem jedan heterologni dio sadrži peptid ili polipeptid koji omogućuje vizualizaciju ili lokalizaciju rekombinantnog FVIII proteina in vitro, in vivo, ex vivo ili bilo koje njihove kombinacije; pri čemu je peptid ili polipeptid koji omogućuje vizualizaciju ili lokalizaciju odabran od:
wherein: the scan index of the last significant coefficient is determined based on the x index and the y index, 
Postupak prema zahtjevu 1, naznačen time da određivanje lokacije zadnjeg značajnog koeficijenta transformacije nadalje sadrži:
In one embodiment, the hydrogenation conditions of part (a) comprises a Pd/C catalyst. 
Metoda 1z zahtjeva 1 pri kojoj hidrogenirajući uvjeti pod stavkom a) podrazumijevaju Pd/C katalizator.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fenpropidin. 
spoja formule (I) [image] naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i spoj mandipropamid.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
A composition according to claim 19, further comprising at least one compound or polypeptide selected from a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (G1) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic drug, an otic drug or nasal drug, a topical drug, a nutritional drug, and a cytokine antagonist. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of the IL-23p19 antibody according to claim 16 . 
Sastav koji obuhvaća najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 i najmanje jedan farmaceutski prihvatljiv nosač ili razblaživač, opcionalno dodatno obuhvaćajući najmanje jedan spoj ili polipeptid izabran od detektabilne oznake, ili reportera, TNF antagonista, anti infektivnog lijeka, lijeka kardiovaskularnog (CV) sustavaa, lijeka centralnog nervnog sustava (CNS), lijeka autonomnog nervnog sustava (ANS), lijeka respiratornog trakta, lijeka gastrointestinalnog (GI) trakta, hormonalnog lijeka, lijeka za ravnotežu tekućine ili elektrolita, hematološkog lijeka, aneoplastičnog, imunomodulacijskog lijeka, oftalmičkog, ušnog ili nazalnog lijeka, topikalnog lijeka, nutricijskog lijeka, citokina i citokin antagonista.
The use of claim 28, wherein said crystalline trans-(±)-A9-tetrahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99%, even more preferably at least 99.5% and most preferably at least 99.9% by weight of the total amount of cannabinoids in said composition. 
Upotreba prema zahtjevu 28, naznačena time da kristalni trans-(±)-A9-tetrahidrokanabinol sadrži barem 95%, poželjno barem 98%, poželjnije barem 99%, još poželjnije barem 99.5% i najpoželjnije barem 99.9% težine ukupne količine kanabinoida u navedenom sastavu.
coupling an amino-terminal protected aspartic acid having a protected carboxyl side chain to a tryptophan-proline dipeptide through the tryptophan of the dipeptide, and removing the amino-terminal protecting group from the aspartic acid, thereby forming a protected 4-6 eptifibatide sequence of the formula: P3-Asp(O—P2)-Trp-Pro-OH; 
P,-Har-Gly-OH; kopuliranje amino-terminalno zaštićenog ostatka aspartinske kiseline, koji ima zaštićen karboksilni postrani lanac, na triptofan-prolin dipeptid preko triptofanskog ostatka dipeptida, i uklanjanje amino-terminalne zaštitne skupine iz ostatka aspartinske kiseline, da na taj način nastane zaštićeni fragment 4-6 eptifibatida formule:
A flexible floating walkway as defined in claim 1 characterised in that the bridge elements are coupled to the floating elements in a way which prevents rotation of the bridge elements about their longitudinal axes. 
Savitljiva plutajuća staza (10) prema zahtjevu 1 ili 2, naznačena time što su mostni elementi (50) spojeni s plutajućim elementima (60A, 60B) na način koji sprječava rotaciju mostnih elemenata (50) oko njihove uzdužne osi
Cancer Type & Cell line MDR Tubulin 
Vrsta karcinoma i stanična linija MDR Tubulin
Additionally, the juicer element 111 may also include an annular stop member 115 positioned at one end of the juicer so as to prevent over-insertion of the juicer element 111 into the blender container 106 . 
Dodatno, sokovnik 111 može također uključiti kružni zaustavni dio 115 smješten na jednome kraju sokovnika tako da sprečava prejako umetanje sokovnika 111 u posudu mješalice 106.
an outlet (14) with a valve for offloading the soil (18) and liquid (20) from the holding space; characterised in that the hold offloading system further comprises 
izlaz (14) s ventilom za istovar zemlje (18) i tekućine (20) iz prostora za držanje;
adding to said water-phase vessel of step b, a chelating agent, selected from a group comprising Disodium EDTA and the like, either singly or any combination thereof, in an amount between 0.01% (w/w) to 1% (w/w), preferably 0.5% (w/w), more preferably 0.1% (w/w), 
dodavanje u navedenu posudu s vodenom fazom iz stupnja b agensa za keliranje koji se odabire iz skupine koja sadrži dinatrijevu EDTA i slične, ili pojedinačno ili bilo koju njihovu kombinaciju u količini između 0,01% (tež.) do 1% (tež.), prvenstveno 0,5% (tež.), pogodnije 0,1% (tež.),
0.5-3% (w/w) of a difunctional acrylate or methacrylate cross-linking monomer of formula [2]: wherein 
0,5 do 3 % (težinski) difunkcionalnog akrilatnog ili metakrilatnog monomera za umrežavanje formule [2]:
q represents an integer of 1 or 2; 
q predstavlja cijeli broj 1 ili 2;
The method of claim 8 or claim 10 wherein the primary drive signal is applied continuously and the secondary drive signal is pulsed. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time, da je sustav namješten tako da se primarni pokretački signal primjenjuje neprekidno i daje impuls sekundarnom pokretačkom signalu.
The method according to Claim 15, wherein said antigen-presenting cell comprises an expression vector according to Claim 8. 
Metoda iz Zahtjeva 13, gdje se stanica koja prikazuje antigen sastoji od vektora ekspresije prema Zahtjevu 6.
is selected from hydrogen, halo, and methyl; 
R* je odabrano od vodik, halo, i metil;
the processing circuitry of the wireless device is configured to execute a client software application associated with the server software application. The wireless communications network of any of claims 11 to 14, wherein: the processing circuitry of the server node is configured to execute a server software application; and 
Bežični uređaj u skladu s bilo kojim od patentnih zahtjeva 46-52, naznačen time što je sklopovlje za obradu dodatno konfigurirano za: zahtijevanje dodatnih informacija o sustavu iz mreže za bežične komunikacije; i primanje dodatnih informacija o sustavu iz mreže za bežične komunikacije, u odgovor na navedeni zahtjev.
A process for producing compounds of Formula (I) according to claims 1 to 4, comprising The step of reacting compound II Wherein R1, R2, R4 and n are as defined in claim 1 and wherein PG1 denotes H or a nitrogen protecting group, with compound of Formula (III) Wherein Q, E and R3 are as defined in claim 1 
Postupak za proizvodnju spojeva formule (I) prema zahtjevima 1 do 4, naznačen time da sadrži korak reakcije spoja II [image] pri čemu R1, R2, R4 i n su kako je definirano u zahtjevu 1 i pri čemu PG1 označava H ili dušikove zaštitne skupine, sa spojem s Formulom (III) [image] pri čemu Q, E i R3 su kako je definirano u zahtjevu 1.
Diseases or disorders that can be treated with the provided compositions include but are not limited to rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Wegener's disease (granulomatosis), Crohn's disease (or inflammatory bowel disease), chronic obstructive pulmonary disease (COPD), Hepatitis C, endometriosis, asthma, cachexia, psoriasis, and atopic dermatitis. 
Kompozicija prema bilo kojem od patentnih zahtjeva 1 do 9 za upotrebu u liječenju reumatoidnog artritisa, psorijaznog artritisa, ankilozirajućeg spondilitisa, Vegenerove bolesti (granulomatoze), Kronove bolesti, inflamatorne bolesti crijeva, kronične opstruktivne bolesti pluća (COPD), hepatitisa C, endometrioze, astme, kaheksije, psorijaze ili atopijskog dermatitisa.
wherein the degree of change in the normalized frequency will be dependent on the fractional concentration of fetal nucleic acids in the analyzed sample. The method of claim 17, wherein the relative size of chromosome 21 compared with the other chromosomes is taken into account when obtaining the normalized frequency. A computer program product comprising a computer readable medium encoded with a plurality of instructions for controlling a computing system to perform an operation for performing prenatal diagnosis of a fetal chromosomal aneuploidy in a biological sample obtained from a pregnant female subject, wherein the biological sample includes nucleic acid molecules, the operation comprising the steps of: 
Proizvod računalnog programa, naznačen time, da obuhvaća čitljiv računalni medij koji je kodiran s većim brojem uputa za upravljanje računalnim sustavom u svrhu izvođenja radne operacije prednatalne dijagnoze fetalne kromosomske aneuploidije u biološkom uzorku dobivenom od trudne ženske osobe, pri čemu biološki uzorak je plazma iz maternice i uključuje molekule nukleinske kiseline, dok radna operacija sadrži sljedeće korake: zaprimanje podataka iz nasumičnog sekvencijskog postupka na dijelu molekula nukleinske kiseline, koje su sadržane u biološkom uzorku od trudne ženske osobe, gdje biološki uzorak uključuje molekule nukleinske kiseline, dok njihov navedeni dio predstavlja frakciju humanog genoma;
or Figure 7, and/or in Figure 7A or 7B, wherein the X-Ray Powder Diffraction data is collected on a diffractometer operating with a copper anode and a nickel filter 
[image] ili slici 7, i/ili slici 7A ili 7B, pri čemu su podaci o difrakciji X-zraka na praškastom uzorku dobijeni pomoću difraktometra sa bakarnom anodom i filterom od nikla.
The resulting organic solution was extracted with 10% aqueous NH40H (2 x 2 I.). 
Dobivena organska otopina se ekstrahira sa 10% vodenim MH4OH (2x2 1.).
H-Asp(O—P2)-Trp-Pro-OH through attachment of the Gly of the 2-3 eptifibatide sequence to the Asp of the 4-6 eptifibatide sequence, thereby forming the 2-6 eptifibatide sequence. 
H-Asp(O-P>)-Trp-Pro-OH spajanjem rezidua Gly fragmenta 2-3 eptifibatida na reziđduum Asp fragmenta 4-6 eptifibatida, čime se formira fragment 2-6 eptifibatida
PRIORITY CLAIM This application: 
Broj međunarodne prijave:
turning the locking pin of the at least one locking device relative to the sleeve associated with the locking pin by the at least one electric motor. 
- < zakretanje najmanje jednog zapornog klina (9) u odnosu na naglavak (10) koji je udružen s navedenim zapornim klinom (9), pomoću najmanje jednog električnog motora (4).
Another aspect of the present invention pertains to compounds of Formula (I), as described herein, for use in a method of treatment of a metabolic-related disorder of the human or animal body by therapy wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes. 
Slijedeći aspekt prikazanog izuma odnosi se na spojeve Formule (I), kako je već ovdje opisana, za uporabu u postupcima liječenja metabolički pripadajućih poremećaja ljudskog ili životinjskog tijela terapijom gdje je navedeni metabolički pripadajući poremećaj izabran iz skupine koju čine dislipidemija, ateroskleroza, koronarno srčano oboljenje, inzulinska rezistencija i dijabetes tipa 2.
In this embodiment, for example, the duration of the active OFDM symbol may be 448 µs (at 4k FFT mode for 8MHz bandwidth CATV systems) or 597 µs (at 4k FFT mode for 6MHz bandwidth CATV systems). 
Uređaj prema zahtjevu 5, gdje je vrijednost aktivnog OFDM polja trajanja simbola jedna od 448 us na 4k FFT, mod za prijenosni sustav od 8 MHz širine pojasa 1 448 x (8/6) us na 4k FFT mod za prijenosni sustav od 6 MHz širine pojasa.
Last but not least, the processes according to the invention also allow the manufacture of variously structured and striated, thin, linear looking veneers. 
I na kraju, ali ne i manje važno, postupak koji je u skladu s ovim izumom također omogućava proizvodnju različito strukturiranih i iscrtanih, tankih furnira koji imaju pravocrtan izgled.
The solvent was evaporated in vacuo and the residue dissolved in chloroform (3 L) and washed with 10% aqueous ammonia (2 x 2 L), and the organic phase was dried over magnesium sulphate and the solvent evaporated in vacuo. 
Otapalo se otpari u vakuumu, ostatak otopi u kloroformu (3 1), te ispere 10 % vodenom otopinom amonijaka (2 X 2 1), organsku fazu osuši preko magnezijevog sulfata, a otapalo otpari u vakuumu.
The compound, the pharmaceutically acceptable salt thereof or a prodrug thereof according to 13, wherein R4a is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group. 
Spoj u skladu s patentnim zahtjevom 3, ili njegova farmaceutski prihvatljiva sol, gdje R* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom, halogen-C;.4 alkilnom skupinom, Ci.4 alkoksi skupinom ili halogen-C;.4 alkoksi skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom ili C;.4 alkoksi skupinom.
Commercial available aminomethylpolystyrene resin (30.4 g, 41.07 mmol), pretreated with DMF, reacted at RT overnight with a solution of 4-(hydroxyl-diphenyl-methyl)benzoic acid (15.0 g, 49.28 mmol, 1.2 equiv. 
Komercijalno raspoloživa aminometilpolistirenska smola (30.4 g, 41.07mmol), pre-tretirana s DMF-om, reagira na RT preko noći s otopinom 4-(hidroksil-difenil-metil) benzojeve kiseline (15.0 g, 49.28 mmol, 1.2 equiv.
The human T cell of claim 16, wherein the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:8. 
(v1) CAR je kodiran sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8.
There are several types of transdermal formulations of buprenorphine reported in the literature. 
U literaturi je navedeno više tipova transdermalnih formulacija buprenorfina.
treating Compound 35 with an alcohol at an elevated temperature to produce Compound 36: 
reakciju akroleina sa CH3NO2 da bi se proizveo spoj 8: [image]
a compound where R5 is a hydrogen atom, hydroxyl group, methyl group, ethyl group, methoxy group, ethoxy group, or a fluorine atom, or a salt thereof, or a solvate of these; 
Spoj ilin njegova sol ili solvat u skladu s bilo kojim patentnim zahtjevom 1 do 8, naznačen time, da je R" atom vodika, hidroksilna skupina, metilna skupina, etilna skupina, metoksi skupina, etoksi skupina ili atom fluora,
The 5-fluorouracil derivative or a salt thereof according to Item 1 or 2, wherein R1 represents a hydrogen atom, an allyl group, a benzyl group, an aliphatic acyl group, an aromatic acyl group, or an alicyclic acyl group, R2 represents a lower alkoxymethyl group in which the lower alkoxy moiety has 1 to 6 carbon atoms or a tetrahydrofuranyl group, X represents a carbon atom or a nitrogen atom, and Y represents a fluorine atom or a chlorine atom. 
O . Derivat 5-fluorouracila ili njegova sol, prema zahtjevu 1 ili 2, naznačen time, da R! predstavlja atom vodika, alil-skupinu, benzil-skupinu, alifatsku acil-skupinu, aromatsku acil-skupinu, ili alicikličku acil-skupinu, R7 predstavlja nižu alkoksimetil-skupinu u kojoj niži alkoksi-dio skupine ima od jednog do šest atoma ugljika, ili tetrahidrofuranil-skupinu, X predstavlja atom ugljika ili atom dušika, a Y predstavlja atom fluora ili atom klora.
contacting the water and/or sludge and/or sediment of step a) with the at least one surface-treated calcium carbonate of step b) for obtaining a composite material of surface-treated calcium carbonate and impurities, wherein the surface-treated calcium carbonate comprises a surface-modified calcium carbonate that has been processed with cationic polymers through an additional treatment step, wherein the surface-modified calcium carbonate is obtained by reacting a natural calcium carbonate and/or precipitated calcium carbonate with an acid and with carbon dioxide prior to the preparation of the surface-treated calcium carbonate, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source. 
dovođenje u kontakt vode i/ili mulja i/ili taloga iz koraka a) sa barem jednim površinski tretiranim kalcij karbonatom koraka b) kako bi se dobio kompozitni materijal površinski tretiranog kalcij karbonata i nečistoća, pri čemu površinski tretirani kalcij karbonat sadrži površinski modificirani kalcij karbonat koji je bio procesiran sa kationskim polimerima kroz dodatni korak obrade, pri čemu je površinski modificirani kalcij karbonat dobiven reagiranjem prirodnog kalcij karbonata i/ili istaloženog kalcij karbonata sa kiselinom i ugljik dioksidom prije priprave površinski tretiranog kalcij karbonata, pri čemu je ugljik dioksid dobiven in situ kiselinskom obradom i/ili je doveden iz vanjskog izvora.
In another embodiment, the invention relates to a humanized antibody or antibody fragment having a heavy chain variable domain and a light chain variable region comprising the amino acid sequences of SEQ ID NO:35 and SEQ ID NO:31, respectively. 
HR P20180542 T1 PATENTNI ZAHTJEVI Humanizirano protutijelo, naznačeno time što ima teški lanac i laki lanac, koji imaju aminokiselinske sljedove SEQ ID NO:35 odnosno SEQ ID NO:31.